Deerfield Management Company »

Ocular Therapeutix shares owned by Deerfield Management Company

Quarter-by-quarter ownership of Ocular Therapeutix (OCUL) shares owned by Deerfield Management Company from 13F filings

Historical chart of Deerfield Management Company investment in Ocular Therapeutix

Tip: Access up to 7 years of quarterly data

All positions including Ocular Therapeutix held by Deerfield Management Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Ocular Therapeutix by Deerfield Management Company

Quarter filed Position value Share count Share price at filing
2023-12-31 $85k 19k 4.46

More positions owned by Deerfield Management Company

Nuvalent Inc-a (NUVL)
Glaukos Corp Note 2.750% 6/1 (Principal)
Viatris (VTRS)
Invitae Corp Debt 4.500% 3/1 (Principal)
Natera Note 2.250% 5/0 (Principal)
Catalyst Pharmaceutical Partners (CPRX)
Centene Corporation (CNC)
Brookdale Sr Living Note 2.000%10/1 (Principal)
Insmed Note 1.750% 1/1 (Principal)
Neurocrine Biosciences (NBIX)
Accolade Note 0.500% 4/0 (Principal)
Oscar Health Cl A (OSCR)
Owens & Minor (OMI)
Adapthealth Corp Common Stock (AHCO)
Springworks Therapeutics (SWTX)

View all positions for Deerfield Management Company

Top funds holding Ocular Therapeutix

VR Adviser
Summer Road
Opaleye Management
Vanguard Group
Franklin Resources
Logos Global Management
Citadel Advisors
Deltec Asset Management
Millennium Management
Dr. Jeffrey R. Jay, M.D.
Banco Santander
Artia Global Partners
D. E. Shaw & Co
Essex Investment Management
Bank of New York Mellon

View all funds holding Ocular Therapeutix